Subtopic Deep Dive
Hyperuricemia Prophylaxis in Chemotherapy
Research Guide
What is Hyperuricemia Prophylaxis in Chemotherapy?
Hyperuricemia prophylaxis in chemotherapy prevents elevated uric acid levels and acute kidney injury during tumor lysis syndrome in leukemia and lymphoma patients using allopurinol, rasburicase, or combinations.
Studies compare rasburicase and allopurinol for efficacy in high-risk pediatric and adult patients undergoing induction chemotherapy. Rasburicase rapidly reduces uric acid via enzymatic oxidation, outperforming allopurinol in randomized trials (Goldman et al., 2001; 472 citations; Pui et al., 2001; 362 citations). Expert consensus recommends risk-stratified prophylaxis with hydration and uricolytic agents (Cairo et al., 2010; 539 citations). Over 2,000 citations across 10 key papers guide clinical protocols.
Why It Matters
Prophylaxis preserves renal function, allowing full chemotherapy doses and reducing mortality in acute leukemias and lymphomas. Rasburicase prevents hyperuricemia better than allopurinol in children at high TLS risk, minimizing AKI (Goldman et al., 2001). In adults with aggressive NHL, rasburicase during induction lowers uric acid levels and TLS incidence (Coiffier et al., 2003). Guidelines from Cairo et al. (2010) and Jones et al. (2015) standardize prophylaxis, improving oncologic outcomes in high-burden malignancies.
Key Research Challenges
Rasburicase Cost Barriers
High cost of rasburicase limits access despite superior efficacy over allopurinol in pediatric leukemia (Goldman et al., 2001; 472 citations). Compassionate-use trials confirm effectiveness but highlight economic constraints (Pui et al., 2001). Balancing cost with AKI prevention remains unresolved.
Risk Stratification Accuracy
Predicting TLS in AML patients is imperfect, with models identifying factors but varying clinical TLS rates (Montesinos et al., 2007; 216 citations). Consensus panels note challenges in uniform risk evaluation across adults and children (Cairo et al., 2010). Improved biomarkers are needed.
Adult vs Pediatric Differences
Pediatric trials favor rasburicase, but adult NHL data show mixed renal outcomes (Coiffier et al., 2003; 238 citations). Guidelines adapt prophylaxis differently by age (Jones et al., 2015; 199 citations). Harmonizing regimens across populations lacks head-to-head trials.
Essential Papers
Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus
Mitchell S. Cairo, Bertrand Coiffier, Alfred Reiter et al. · 2010 · British Journal of Haematology · 539 citations
Summary Tumour lysis syndrome (TLS) is a life‐threatening oncological emergency characterized by metabolic abnormalities including hyperuricaemia, hyperphosphataemia, hyperkalaemia and hypocalcaemi...
A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis
Stanton Goldman, John S. Holcenberg, Jerry Z. Finklestein et al. · 2001 · Blood · 472 citations
Abstract Standard therapy in the United States for malignancy-associated hyperuricemia consists of hydration, alkalinization, and allopurinol. Urate oxidase catalyzes the enzymatic oxidation of uri...
Recombinant Urate Oxidase for the Prophylaxis or Treatment of Hyperuricemia in Patients With Leukemia or Lymphoma
Ching‐Hon Pui, Hazem H. Mahmoud, Joseph M. Wiley et al. · 2001 · Journal of Clinical Oncology · 362 citations
PURPOSE: To improve the control of hyperuricemia in patients with leukemia or lymphoma, we tested a newly developed uricolytic agent, recombinant urate oxidase (SR29142; Rasburicase; Sanofi-Synthel...
Efficacy and Safety of Rasburicase (recombinant urate oxidase) for the Prevention and Treatment of Hyperuricemia During Induction Chemotherapy of Aggressive Non-Hodgkin’s Lymphoma: Results of the GRAAL1 (Groupe d’Etude des Lymphomes de l’Adulte Trial on Rasburicase Activity in Adult Lymphoma) Study
Bertrand Coiffier, Nicolas Mounier, Serge Bologna et al. · 2003 · Journal of Clinical Oncology · 238 citations
Purpose: Hyperuricemia and tumor lysis syndrome are well-known complications during induction treatment of aggressive non-Hodgkin’s lymphomas (NHLs). Usual prophylaxis and treatment of hyperuricemi...
Tumor lysis syndrome in patients with acute myeloid leukemia: identification of risk factors and development of a predictive model
Pau Montesinos, I Di Lorenzo, Guillermo Martı́n et al. · 2007 · Haematologica · 216 citations
TLS is frequently observed in AML patients during induction therapy. Only the development of CTLS had an impact on higher mortality rate from induction therapy. The scoring system derived from this...
Guidelines for the management of tumour lysis syndrome in adults and children with haematological malignancies on behalf of the British Committee for Standards in Haematology
Gail Jones, Andrew Will, Graham Jackson et al. · 2015 · British Journal of Haematology · 199 citations
The guideline group was selected to be representative of UK-based medical experts. Recommendations are based on review of the literature using MEDLINE and PUBMED up to December 2013 under the headi...
Nephrotoxicity as a cause of acute kidney injury in children
Ludwig Patzer · 2008 · Pediatric Nephrology · 151 citations
Reading Guide
Foundational Papers
Start with Cairo et al. (2010; 539 citations) for TLS risk/prophylaxis consensus, then Goldman et al. (2001; 472 citations) for pediatric rasburicase RCT, and Pui et al. (2001; 362 citations) for leukemia/lymphoma applications.
Recent Advances
Jones et al. (2015; 199 citations) updates UK guidelines; Mirrakhimov (2015; 128 citations) reviews TLS mechanisms.
Core Methods
Rasburicase (recombinant urate oxidase) oxidizes uric acid; allopurinol inhibits xanthine oxidase; risk models score tumor burden, renal function, lab values (Montesinos et al., 2007).
How PapersFlow Helps You Research Hyperuricemia Prophylaxis in Chemotherapy
Discover & Search
Research Agent uses searchPapers and citationGraph on Cairo et al. (2010; 539 citations) to map TLS prophylaxis consensus, revealing connections to Goldman et al. (2001) and Pui et al. (2001). exaSearch uncovers risk models like Montesinos et al. (2007), while findSimilarPapers expands to 50+ related trials.
Analyze & Verify
Analysis Agent applies readPaperContent to extract uric acid reduction metrics from Goldman et al. (2001), then verifyResponse with CoVe checks rasburicase superiority claims against Coiffier et al. (2003). runPythonAnalysis computes meta-analysis statistics on AKI rates; GRADE grading scores evidence as high for pediatric prophylaxis.
Synthesize & Write
Synthesis Agent detects gaps in adult AML prophylaxis via contradiction flagging between Cairo et al. (2010) and Montesinos et al. (2007). Writing Agent uses latexEditText, latexSyncCitations for Cairo/Goldman refs, and latexCompile to generate TLS risk diagrams; exportMermaid visualizes prophylaxis algorithms.
Use Cases
"Compare rasburicase vs allopurinol AKI rates in pediatric leukemia using stats"
Research Agent → searchPapers → Analysis Agent → runPythonAnalysis (pandas meta-analysis on Goldman 2001/Pui 2001 uric acid data) → CSV export of RR/OR for AKI prevention.
"Draft TLS prophylaxis guideline citing Cairo 2010 with risk table"
Synthesis Agent → gap detection → Writing Agent → latexEditText (guideline text) → latexSyncCitations (Cairo/Coiffier) → latexCompile → PDF with embedded TLS risk stratification table.
"Find code for TLS risk prediction models from papers"
Research Agent → paperExtractUrls (Montesinos 2007) → Code Discovery → paperFindGithubRepo → githubRepoInspect → Python script for AML TLS scoring system.
Automated Workflows
Deep Research workflow scans 50+ TLS papers starting with citationGraph on Cairo et al. (2010), producing structured review of rasburicase efficacy with GRADE scores. DeepScan applies 7-step CoVe to verify prophylaxis claims across Goldman (2001) and Coiffier (2003), flagging contradictions. Theorizer generates hypotheses on combination allopurinol-rasburicase regimens from guideline gaps (Jones et al., 2015).
Frequently Asked Questions
What is hyperuricemia prophylaxis in chemotherapy?
It uses allopurinol or rasburicase to prevent uric acid buildup and AKI during TLS in leukemia/lymphoma induction (Cairo et al., 2010).
What are key methods for prophylaxis?
Rasburicase enzymatically degrades uric acid faster than allopurinol; hydration and risk stratification are standard (Goldman et al., 2001; Coiffier et al., 2003).
What are seminal papers?
Cairo et al. (2010; 539 citations) provides TLS consensus; Goldman et al. (2001; 472 citations) shows rasburicase superiority in children.
What open problems exist?
Optimal rasburicase dosing in adults, cost-effectiveness, and precise TLS risk models for AML need further trials (Montesinos et al., 2007; Jones et al., 2015).
Research Methemoglobinemia and Tumor Lysis Syndrome with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Hyperuricemia Prophylaxis in Chemotherapy with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers